NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
After making a successful investment in the marijuana market, the company recently expanded into the retail and online sale of cannabidiol (CBD), which has become one of the fastest-growing market categories in the United States.
ChineseInvestors.com, Inc. (OTCQB: CIIX) attended the ‘Invest 2017’ exhibition in Stuttgart, Germany, on April 7-8, 2017, anticipating that the conference would be an opportunity for CIIX to introduce its hemp companies and products to German investors, but CIIX is not alone in seeing the growth opportunities for medical cannabis in that market.
China represents a past civilization that has sprung many surprises over the centuries, and has given us some of our greatest inventions, including the compass, gunpowder, papermaking, and printing. On par with these innovations has been Traditional Chinese Medicine (TCM), which has relied, in part, on herbal remedies (tui na).
In addition to its San Gabriel store, the company also owns and operates an online store based in the free trade zone of Shanghai, China.
How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions?
The Bethesda, Maryland-based company is a first mover in “combination therapies” that merge cannabinoids with existing drugs to provide more effective remedies.
India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease.
Marijuana use is currently illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers in that country.
IGC has filed two patents, IGC-502 and IGC-505, for combination therapies for the treatment of seizures in dogs and cats, which in it itself is a surprisingly large market.
Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids.
Algae Dynamics Corp (OTCQB: ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.
Investors have had their eyes on Algae Dynamics Corp. (OTCQB: ADYNF), which has partnered with various Canadian universities (including the University of Waterloo and Western University) for access to research and to boost its cannabis extraction expertise.
A population of over 1.2 billion people is one heck of a target market, especially when insulated by language. ChineseInvestors.com (OTCQB: CIIX) has leveraged this demographic to market a broad range of products, services and information specifically for the Chinese speaking population.
India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology.
